Table 2:
Serum S100A8/A9 and S100A12 levels according to disease course
| First Phase (n=130) | Second Phase (n=106) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CID maintained | CID lost before withdrawal | P value* | No flare within 8 months | Disease flare | P value* | |||||
| S100A8/A9 | n | S100A8/A9 [ng/ml] | n | S100A8/A9 [ng/ml] | n | S100A8/A9 [ng/ml] | n | S100A8/A9 [ng/ml] | ||
| All patients | 106 | 650 (49–3892) | 24 | 654 (200–2070) | 0.82 | 67 | 584 (71–5009) | 39 | 544 (140–2361) | 0.36 |
| Per JIA category | ||||||||||
| Extended oligoarthritis | 17 | 760 (158–1621) | 1 | 2070 (N/A) | N/A | 9 | 800 (130–4339) | 8 | 500 (160–1276) | 0.55 |
| Seronegative polyarthritis | 78 | 614 (49–3892) | 17 | 528 (230–1839) | 0.25 | 50 | 595 (71–5009) | 30 | 505 (140–2361) | 0.29 |
| Seropositive polyarthritis | 8 | 510 (210–1260) | 1 | 1140 (200–1890) | 0.31 | 8 | 430 (180–950) | 1 | 1541 (N/A) | N/A |
| Per anti-TNF agent | ||||||||||
| Adalimumab | 16 | 930 (133–2180) | 4 | 350 (290–1240) | 0.38 | 9 | 490 (280–1633) | 7 | 307 (140–1276) | 0.17 |
| Etanercept | 86 | 571 (49–3892) | 18 | 654 (200–1890) | 0.92 | 55 | 618 (71–5009) | 31 | 560 (145–2361) | 0.75 |
| Infliximab | 4 | 805 (180–1404) | 2 | 2070 (N/A) | N/A | 3 | 460 (290–1070) | 1 | 281 (N/A) | N/A |
| Per MTX therapy | ||||||||||
| On MTX | 41 | 668 (94–3000) | 13 | 832 (250–2070) | 0.63 | 28 | 920 (160–5009) | 13 | 750 (145–1541) | 0.64 |
| Not on MTX | 65 | 620 (49–3892) | 11 | 482 (200–1890) | 0.28 | 39 | 468 (71–2530) | 26 | 440 (140–2361) | 0.57 |
| S100A12 | n | S100A12 [ng/ml] | n | S100A12 [ng/ml] | n | S100A12 [ng/ml] | n | S100A12 [ng/ml] | ||
| All patients | 106 | 93 (0–1558) | 24 | 100 (13–890) | 0.69 | 67 | 92 (14–1558) | 39 | 94 (0–479) | 0.39 |
| Per JIA category | ||||||||||
| Extended oligoarthritis | 17 | 90 (0–339) | 1 | 890 (N/A) | N/A | 9 | 70 (10–1197) | 8 | 56 (14–186) | 0.70 |
| Seronegative polyarthritis | 78 | 93 (11–1558) | 17 | 91 (13–202) | 0.45 | 50 | 92 (14–1283) | 30 | 73 (11–526) | 0.91 |
| Seropositive polyarthritis | 8 | 114 (17–566) | 1 | 121 (16–326) | 0.91 | 8 | 51 (31–183) |
1 | 297 (N/A) | N/A |
| Per anti-TNF agent | ||||||||||
| Adalimumab | 16 | 115 (14–479) | 4 | 115 (16–326) | 0.80 | 9 | 70 (34–300) | 7 | 66 (16–186) | 0.96 |
| Etanercept | 86 | 90 (0–1558) | 18 | 91 (13–320) | 0.73 | 55 | 93 (10–1283) | 31 | 73 (11–526) | 0.92 |
| Infliximab | 4 | 121 (21–236) | 2 | 457 (24–890) | 0.80 | 3 | 41 (34–120) | 1 | 64 (N/A) | N/A |
| Per MTX therapy | ||||||||||
| On MTX | 41 | 84 (11–1558) | 13 | 83 (16–890) | 0.99 | 28 | 110 (18–1283) | 13 | 62 (11–364) | 0.57 |
| Not on MTX | 65 | 94 (0–1029) | 11 | 103 (13–220) | 0.53 | 39 | 52 (10–246) | 26 | 73 (14–526) | 0.38 |
*
Mann-Whitney test
CID, clinically inactive disease; MTX, methotrexate; N/A, not applicable; TNF, tumor necrosis factor-alpha